ACT Lung Health Intervention: Phase Two

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT06945120
Status
Recruiting
Apply to this trial

Conditions

  • Smoking (Tobacco) Addiction
  • Smoking Behaviors
  • Smoking Cessation
  • Smoking, Cigarette
  • Smoking, Tobacco

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Accepted

Interventions

  • ACT Lung Health Intervention — BEHAVIORAL
    An Asian culture-tailored lung health intervention, which includes individual counseling sessions, family coaching, provision of nicotine replacement therapy (NRT) in the form of patches, lozenges, or chewing gum, and educational materials about low-dose computed tomography (LDCT) for lung cancer screening. The eight weekly, counseling sessions with study staff will be conducted via phone call or the Zoom web-conferencing platform.

Study Details

This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.

Key Dates

Start date
Nov 4, 2025
Status verified
Nov 2025
Primary completion
Nov 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: Group A: ACT Lung Health Intervention
    Participants will be randomized 1:1 in blocks, stratified by ethnicity and readiness to quit smoking and will complete: * Baseline assessment * Eight telephone or video counseling sessions over 8 weeks * Nicotine replacement therapy (NRT) patches, gums and lozenges will be provided * Written educational materials on lung cancer screening will be provided * Assessments at 1, 3, and 6 months * 3 month saliva test * 6 month saliva test
  • No Intervention: Group B: Standard Care
    Participants will be randomized 1:1 in blocks, stratified by ethnicity and readiness to quit smoking and will complete: * Baseline assessment * Six telephone or video counseling sessions over 8 weeks * Nicotine replacement therapy (NRT) patches, gums and lozenges will be provided * Written educational materials on lung cancer screening will be provided * Assessments at 1, 3, and 6 months * 3 month saliva test * 6 month saliva test

Primary Outcome Measure

Biochemically Verified 7-Day Point Prevalence Smoking Abstinence at 6 Months (Group A) [ Time Frame: 6 months post-baseline assessment ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02115
Mary Cooley, PhD
[email protected]
617-632-5096
Barbara Halpenny, MA, MSW
[email protected]
617-582-7124
University of Massachusetts-BostonBostonMassachusetts02125
Sun Kim, PhD, RN
[email protected]
Sohyon Pak, MS
[email protected]
Sun Kim, PhD, RN (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Dana-Farber Cancer Institute· Boston, MAUniversity of Massachusetts-Boston· Boston, MA

Related Studies